Holen Sie sich die Stockscreener-App
49.24
1.82%
0.86
Schlusskurs vom Vortag:
$48.38
Offen:
$48.31
24-Stunden-Volumen:
404.52K
Relative Volume:
0.50
Marktkapitalisierung:
$2.76B
Einnahmen:
$651.97M
Nettoeinkommen (Verlust:
$59.71M
KGV:
46.04
EPS:
1.0696
Netto-Cashflow:
$172.03M
1W Leistung:
+2.48%
1M Leistung:
+8.36%
6M Leistung:
+55.89%
1J Leistung:
+49.64%
1-Tages-Spanne:
$47.98
$49.48
1-Wochen-Bereich:
$47.27
$51.78
52-Wochen-Spanne:
$29.16
$51.78
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Vergleichen Sie SUPN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
49.28 | 2.71B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
143.28 | 63.05B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.79 | 43.33B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.165 | 40.43B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.11 | 22.97B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
434.04 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Why Supernus Pharmaceuticals Inc. stock remains undervaluedTrend Reversal & Precise Buy Zone Identification - newser.com
Is Supernus Pharmaceuticals Inc. stock near bottom after declineMarket Trend Report & Reliable Price Breakout Alerts - newser.com
Supernus Pharmaceuticals Inc Stock Analysis and ForecastGlobal Trade Effects & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Supernus Pharmaceuticals (SUPN) Is Up 2.81% in One Week: What You Should Know - Yahoo Finance
Published on: 2025-10-13 06:52:20 - newser.com
What MACD signals say about Supernus Pharmaceuticals Inc.Wall Street Watch & Daily Stock Trend Watchlist - newser.com
Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines - TradingView
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - sharewise.com
Supernus CEO Khattar sells $3m in shares By Investing.com - Investing.com Canada
Insider Sell Alert: NEWHALL CHARLES W III Sells 25,000 Shares of Supernus Pharmaceuticals Inc (SUPN) - GuruFocus
Supernus Pharmaceuticals Executives Sell Shares - TradingView
SUPN Crosses Above Average Analyst Target - Nasdaq
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Supernus Pharmaceuticals Shares Rise After Piper Sandler Upgrade - MarketScreener
Supernus Pharmaceuticals: A Rising Pharma Contender? - StocksToTrade
Supernus Pharmaceuticals (SUPN) Stock Is Up, What You Need To Know - TradingView
SUPN: Piper Sandler Raises Price Target to $65 and Upgrades Rati - GuruFocus
Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $65 From $40 - MarketScreener
Can Supernus Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Big Picture & Weekly Market Pulse Updates - newser.com
How Supernus Pharmaceuticals Inc. stock performs during Fed tightening cycles2025 Market Outlook & Fast Exit and Entry Strategy Plans - newser.com
Published on: 2025-10-09 05:01:01 - newser.com
Supernus (SUPN) Receives Upgraded Rating Amid Promising Product Outlook - GuruFocus
How to use Fibonacci retracement on Supernus Pharmaceuticals Inc.2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Is now a turning point for Supernus Pharmaceuticals Inc.July 2025 Earnings & Real-Time Sentiment Analysis - newser.com
Supernus Pharmaceuticals Hits New 52-Week High of $49.66 - Markets Mojo
Will Supernus Pharmaceuticals Inc. rebound enough to break evenDollar Strength & Weekly Top Performers Watchlists - newser.com
How geopolitical tensions affect Supernus Pharmaceuticals Inc. stockCPI Data & Comprehensive Market Scan Insights - newser.com
Why Supernus Pharmaceuticals Inc. stock could be next big winnerJuly 2025 Decliners & Community Trade Idea Sharing Platform - newser.com
Using R and stats models for Supernus Pharmaceuticals Inc. forecasting2025 Macro Impact & Reliable Volume Spike Trade Alerts - newser.com
Is Supernus Pharmaceuticals Inc. stock poised for growthPortfolio Growth Summary & Real-Time Market Trend Scan - newser.com
Is Supernus Pharmaceuticals Inc. stock cheap compared to fundamentalsAnalyst Upgrade & Daily Stock Trend Reports - newser.com
Wall Street Zen Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Hold - Defense World
Smart tools for monitoring Supernus Pharmaceuticals Inc.’s price actionQuarterly Portfolio Review & High Conviction Buy Zone Alerts - newser.com
Real time social sentiment graph for Supernus Pharmaceuticals Inc.Trade Volume Summary & Real-Time Buy Zone Alerts - newser.com
Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by GAMMA Investing LLC - Defense World
Supernus Pharmaceuticals stock hits 52-week high at 48.47 USD - Investing.com India
Supernus Pharmaceuticals stock hits 52-week high at 48.47 USD By Investing.com - Investing.com Australia
Supernus Pharmaceuticals (SUPN): Is the Current Share Price a Fair Reflection of Its True Valuation? - Yahoo Finance
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Supernus Pharmaceuticals Inc-Aktie (SUPN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Khattar Jack A. | President, CEO |
Oct 09 '25 |
Sale |
50.57 |
59,900 |
3,029,336 |
1,206,578 |
| NEWHALL CHARLES W III | Director |
Oct 09 '25 |
Sale |
50.77 |
25,000 |
1,269,234 |
104,644 |
0.95%
2.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):